Table 1.
Summary of published peer-reviewed studies showing anti-SARS-CoV-2 activity for MeBlu.
| Assay | Cell Line | IC50 (μM) | Comment | Reference |
|---|---|---|---|---|
| PPI inhibition (SARS-CoV-2-S—hACE2) | N/A | 1–5 | Including VoCs (e.g., delta) | [23] and this work (VoC) |
| SARS-CoV-2 pseudovirus cell entry | HEK293T | 3–5 | Including VoCs (e.g., delta) | [23] and this work (VoC) |
| SARS-CoV-2 antiviral activity | Vero E6 | 1.7 | Inhibition of SARS-CoV-2 (B.1.5) replication | This work |
| Binding to SARS-CoV-2 S RBD | N/A | 0.36 | Bio-layer interferometry | [35] |
| SARS-CoV-2 antiviral activity | Vero E6 | ~0.3 | Also active against influenza virus H1N1 | [36] |
| SARS-CoV-2 antiviral activity | Vero E6 | 0.4–1.1 | clinically isolated SARS-CoV-2 strains (IHUMI-3 and IHUMI-6) | [37,38] |
| SARS-CoV-2 cytopathicity | Caco-2 | 2.03 | HTS hit, confirmed in concentration response (Supp Info in Res Square preprint) | [39] |
| VSV-SARS-CoV-2-Sdel18 pseudovirus entry | Vero E6 | 9 | HTS hit, confirmed in concentration response | [40] |
| Image-based multicycle replication assay (hCoV-229E) | Huh7 | 1.4 | HTS hit, confirmed in concentration response | [41] |